Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

被引：37
|
作者：
Lee, Sung Won [1 ,2 ]
Choi, Jonggi [3 ]
Kim, Seung Up [4 ,5 ]
Lim, Young-Suk [3 ]
机构：
[1] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Catholic Univ, Liver Res Ctr, Seoul, South Korea
[3] Univ Ulsan, Liver Ctr, Asan Med Ctr, Dept Gastroenterol,Coll Med, Seoul, South Korea
[4] Yonsei Univ, Inst Gastroenterol, Dept Internal Med, Coll Med, Seoul, South Korea
[5] Severance Hosp, Yonsei Liver Ctr, Seoul, South Korea
来源：
CLINICAL AND MOLECULAR HEPATOLOGY | 2021年 / 27卷 / 03期
关键词：
Entecavir; Tenofovir; Hepatitis B; Carcinoma; Hepatocellular; Efficacy; Outcome; DISOPROXIL FUMARATE; RISK; CIRRHOSIS;
D O I：
10.3350/cmh.2021.0179
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.
引用
收藏
页码：402 / 412
页数：11
相关论文
共 50 条
  • [31] Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir
    Chang, Jin Won
    Lee, Jae Seung
    Lee, Hye Won
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Seo, Yeon Seok
    Lee, Han Ah
    Kim, Mi Na
    Lee, Yu Rim
    Hwang, Seong Gyu
    Rim, Kyu Sung
    Um, Soon Ho
    Tak, Won Young
    Kweon, Young Oh
    Park, Soo Young
    Kim, Seung Up
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (01) : 95 - 104
  • [32] Lower risk of hepatocellular carcinoma among patients with chronic hepatitis B treated with tenofovir than entecavir
    Young-Suk Lim
    Cancer Biology & Medicine, 2018, 15(S1) (S1) : 19 - 20
  • [33] Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir? Reply
    Yip, Terry Cheuk-Fung
    Wong, Grace Lai-Hung
    GASTROENTEROLOGY, 2020, 158 (08) : 2312 - 2313
  • [34] Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir/tenofovir in South Korea
    Yu, Jung Hwan
    Jin, Young-Joo
    Lee, Jin-Woo
    Lee, Don-Haeng
    HEPATOLOGY RESEARCH, 2018, 48 (11) : 862 - 871
  • [35] Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee
    Young Youn Cho
    Hyein Lee
    Jae Seung Lee
    Seung Up Kim
    Jun Yong Park
    Do Young Kim
    Sang Hoon Ahn
    Beom Kyung Kim
    Soo Young Park
    Hepatology International, 2021, 15 : 1083 - 1092
  • [36] Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance
    Lee, S.
    Ahn, S. H.
    Jung, K. S.
    Kim, D. Y.
    Kim, B. K.
    Kim, S. U.
    Baatarkhuu, O.
    Ku, H. J.
    Han, K.
    Park, J. Y.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (02) : 141 - 147
  • [37] Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis
    Cheung, Ka Shing
    Mak, Lung Yi
    Liu, Sze Hang
    Cheng, Ho Ming
    Seto, Wai Kay
    Yuen, Man Fung
    Lai, Ching Lung
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2020, 11 (10) : e00236
  • [38] Entecavir versus tenofovir disoproxil fumarate on the reduction of incidence of hepatocellular carcinoma in patients with chronic hepatitis B-related liver cirrhosis
    Lin, Yu-Hung
    Lai, Huang-Lun
    Wang, Chun-Hsiang
    Chang, Kuo-Kuan
    Mo, Lein-Ray
    Lin, Ruey-Chang
    ADVANCES IN DIGESTIVE MEDICINE, 2024, 11 (01) : 16 - 23
  • [39] Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis
    Gu, Lihu
    Yao, Qigu
    Shen, Zefeng
    He, Ying
    Ng, Derry Minyao
    Yang, Tong
    Chen, Bangsheng
    Chen, Ping
    Mao, Feiyan
    Yu, Qili
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (09) : 1467 - 1476
  • [40] Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis
    Dave, Shravan
    Park, Sooyoung
    Murad, M. Hassan
    Barnard, Abbey
    Prokop, Larry
    Adams, Leon A.
    Singh, Siddharth
    Loomba, Rohit
    HEPATOLOGY, 2021, 73 (01) : 68 - 78
12345